Abstract
Despite decades of clinical advancement, many acute, chronic, and progressive lung diseases, such as acute lung injury (ALI), idiopathic pulmonary fibrosis (IPF), lymphangioleiomyomatosis (LAM), and asthma, remain incurable with limited therapeutic options and high morbidity and mortality. Collectively, asthma, IPF, ALI, and LAM impose an annual health care burden exceeding US$100 billion worldwide, reflecting high hospitalization and treatment costs and underscoring the urgent need for basic and translational research to develop effective therapies that reduce morbidity, mortality, and economic impact. The pathophysiology of these diseases is highly complex, driven by the interplay of aging, environmental exposures, genetic susceptibility, cellular heterogeneity, dynamic tissue remodeling, and immune dysregulation. Therefore, it is imperative to investigate the mechanistic underpinnings of disease pathobiology beyond clinical observations and patient-based studies alone. In this context, preclinical and translational research using advanced in vitro cell and ex vivo tissue systems, animal models, and multiomics technologies serves not merely as a complementary approach but rather the essential foundation for translating fundamental discoveries into novel clinical interventions. This issue of Seminars in Respiratory and Critical Care Medicine brings together a collection of articles that collectively underscore the indispensable role of basic and translational science in shaping the future of pulmonary medicine. From dissecting the molecular underpinnings of fibroblast activation in IPF to unraveling the immune-regulatory functions of T cells and macrophages in lung injury and repair in basic translational research. Preclinical models of pulmonary fibrosis are indispensable for dissecting the cellular and molecular mechanisms driving fibrotic lung remodeling, enabling the identification and validation of therapeutic targets that cannot be fully explored through patient studies alone. The bleomycin-induced lung injury model remains the most widely used and well-characterized experimental system for studying pulmonary fibrosis. As reviewed by Brazee et al, this model offers a reproducible framework to investigate the temporal progression of fibrosis from acute inflammation to fibroproliferation followed by spontaneous resolution.[1] While it does not fully recapitulate the histopathological hallmarks of IPF, such as honeycomb cysts and fibroblastic foci, it has nonetheless been instrumental in the preclinical validation of interstitial lung diseases' FDA-approved therapies pirfenidone and nintedanib. Importantly, refinements to the bleomycin model, such as repetitive dosing, use of aged mice, targeted genetic mutations, and combination injury approaches, have enhanced its translational relevance. These adaptations allow researchers to mimic persistent and progressive fibrosis, better reflecting the clinical trajectory of IPF. Moreover, the bleomycin model's flexibility enables interrogation of the time after injury, sex, strain, microbiome, and environmental influences on disease susceptibility and therapeutic response. It is only in understanding and capitalizing on these insights that will allow for better therapeutic development and the identification of novel disease-based biomarkers as highlighted by Schott et al.[2] Additionally, utilizing the correct in vivo models remains critical for developing personalized treatment strategies and for understanding disease heterogeneity. Singh et al provide a comprehensive analysis of fibroblast heterogeneity and activation in pulmonary fibrosis.[3] Their work highlights the diverse cellular origins of myofibroblasts, including resident alveolar fibroblasts, and the transcriptional programs that govern their differentiation and persistence during fibrosis. The identification of key regulators, such as TGF-β, PDGF, Wnt ligands, and transcription factors like SMADs, STATs, WT1, and Sox9, offers promising opportunities as therapeutic targets to halt or reverse the profibrotic pathogenesis associated with these critical cells. Additionally, these findings underscore the value of state-of-the-art technologies, including lineage tracing, single-cell RNA sequencing, and spatial transcriptomics, which have allowed researchers to follow and determine mesenchymal cell fate decisions, differentiation pathways, and intercellular communication within the fibrotic niche. Such technologies, when applied to animal models and in vitro human cells and ex vivo human tissue samples, allow research to bridge the gap between molecular discovery and clinical application, enabling the development of targeted antifibrotic therapies. The complexity of the immune system and its role in pulmonary diseases has been a challenge to study, with exact homologs of human immune cell populations not always being present within murine lungs. However, the importance and contribution of the immune system to every stage of pulmonary disease: Initiation, development, progression, and eventual resolution cannot be underestimated. The article by Pastore et al delves into the immunoregulatory functions of T regulatory cells (Tregs) in airway and ILDs.[4] Their work reveals how Tregs adapt to microenvironmental cues, acquiring phenotypes that either suppress inflammation or contribute to pathogenic remodeling. In asthma, for instance, Tregs can be skewed toward a Th2-like profile, undermining their suppressive capacity and exacerbating disease. Aging, hormonal changes, and genetic polymorphisms further modulate Treg function, highlighting the need for age- and sex-specific therapeutic approaches. Complementing this, Bersie and McCubbrey discuss and explore the heterogeneity of lung phagocytes and their role in clearing apoptotic cells during a process known as efferocytosis.[5] Efficient efferocytosis by alveolar macrophages, interstitial macrophages, dendritic cells, epithelial...